Technology | Cath Lab | February 07, 2018

Teleflex Launches Next-Generation Sympro Elite and Expro Elite Snares

Latest versions of 0.035-inch snares offer clinical versatility in retrieving or repositioning intravascular devices for peripheral procedures

Teleflex Launches Next-Generation Sympro Elite and Expro Elite Snares

February 7, 2018 — Teleflex Inc. has announced 510(k) clearance by the U.S. Food and Drug Administration (FDA) and U.S. commercial launch of new versions of its Expro Elite and Sympro Elite Snares for manipulating interventional devices in peripheral procedures.

Both the Expro Elite and Sympro Elite Snares represent next-generation versions of the 0.035-inch interventional snares originally launched in the U.S. in 2008 by Vascular Solutions, now a wholly-owned subsidiary of Teleflex Inc.

Stewart Strong, president and general manager of the Interventional business unit of Teleflex, said both snare products feature:

  • A durable nitinol construction that retains its shape and adds strength;
  • A radiopaque gold-plated tungsten coil and tip for enhanced visibility;
  • 1:1 torque response for controlled positioning and better access to distal targets; and
  • A unique locking handle that facilitates secure capture.

The Expro Elite Snare uses a helical loop for capture in all directions. The Sympro Elite Snare uses a 90-degree loop that remains coaxial to the vessel lumen for easy capture. Both snare products feature a preassembled, one-piece design that allows rapid deployment through any 0.035-inch compatible lumen. Both the Expro Elite and Sympro Elite Snares are available in 5, 10, 15, 25 and 35 mm loop diameters for clinical versatility. Both snares are 150 cm in length and are packaged one per box.

Both snares are intended for use in the cardiovascular system and hollow viscus to retrieve and/or manipulate objects using minimally-invasive surgical procedures. Manipulation procedures include retrieval and/or repositioning of intravascular foreign objects such as coils, balloons, catheters, and/or guidewires within the cardiovascular system. The devices are not intended for use in the coronary arteries or neurovasculature.

For more information: www.teleflex.com

 


Related Content

News | Cath Lab

December 20, 2023 — Jason R. McCarthy, Ph.D., associate professor of biomedical research and translational medicine and ...

Home December 20, 2023
Home
News | Cath Lab

October 26, 2023 — Royal Philips, a global leader in health technology, announced the latest results demonstrating the ...

Home October 26, 2023
Home
News | Cath Lab

October 25, 2023 — Shockwave Medical, Inc., a pioneer in the development and commercialization of transformational ...

Home October 25, 2023
Home
News | Cath Lab

October 20, 2023 — Over the coming days, Philips will be presenting its latest solutions in cardiology and new late ...

Home October 20, 2023
Home
News | Cath Lab

October 16, 2023 — GE HealthCare (Nasdaq: GEHC) announced US FDA 510(k) clearance of Allia IGS Pulse - the latest ...

Home October 16, 2023
Home
News | Cath Lab

October 16, 2023 — Shimadzu Medical Systems USA, a subsidiary of Shimadzu Corporation, announced the first U.S ...

Home October 16, 2023
Home
News | Cath Lab

September 13, 2023 — A diagnostic test, first offered in the United States at University Hospitals (UH) Harrington Heart ...

Home September 13, 2023
Home
News | Cath Lab

August 2, 2023 — Teleflex Incorporated, a leading global provider of medical technologies, announced the U.S Food and ...

Home August 02, 2023
Home
News | Cath Lab

July 13, 2023 — Mount Sinai Queens announced the opening of a new cardiac catheterization lab that will provide rapid ...

Home July 13, 2023
Home
News | Cath Lab

June 21, 2023 — Royal Philips, a global leader in health technology, announced it has teamed up with BIOTRONIK (Lake ...

Home June 21, 2023
Home
Subscribe Now